Pan-ELR<+> CXC chemokine antibodies
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- ELI LILLY & CO
- Publication Date
- 2019-01-04
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] This application is a Chinese patent application 201480013248.X "Pan-ELR" with the filing date of March 5, 2014 + Divisional application of "CXC Chemokine Antibody". Technical field
[0002] The present invention relates to antibodies against ELR+CXC chemokines and their use in the treatment of diseases mediated by ELR+CXC chemokines. Background technique
[0003] ELR+ CXC chemokines (so called because members of the chemokine family have ELR amino acid motifs next to their CXC motifs) play an important role in various pathogenesis, including neutrophils to inflammation and blood vessels Generate site migration. Neutrophils contribute to the onset of several acute and chronic inflammatory / autoimmune diseases, such as inflammatory bowel disease (IBD), psoriasis, and palmoplantar pustulosis. ELR+ CXC chemokines also play a key role in tumor formation and tumor metastasis. These chemokines are highly expressed in tumors. In the tumor environment, ELR+CXC chemokines are inv...